Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

The Lancet ◽  
2007 ◽  
Vol 369 (9574) ◽  
pp. 1711-1723 ◽  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Treatment ◽  
Hormone Receptor ◽  
Luteinising Hormone ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Releasing Hormone ◽  
Hormone Receptor Positive ◽  
Premenopausal Patients ◽  
Positive Breast Cancer

scholarly journals The Examination of Ovarian Reserve in Premenopausal Patients with Hormone Receptor Positive Breast Cancer

2017 ◽  
Vol 40 (3) ◽  
pp. 104
Author(s):  
Hyun-Ah Kim ◽  
Joohyun Woo ◽  
Hyang Suk Choi ◽  
Seok Joon Lee ◽  
Jihye Choi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Reserve ◽  
Hormone Receptor ◽  
Hormone Receptor Positive ◽  
Premenopausal Patients ◽  
Positive Breast Cancer

Update of the Oxford Overview: New Insight and Perspectives in the Era of Personalized Medicine

2012 ◽  
pp. 71-79
Author(s):  
Kathleen I. Pritchard ◽  
Jonas Bergh ◽  
Harold J. Burstein
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Meta Analysis ◽  
Breast Cancers ◽  
Breast Cancer Therapy ◽  
Hormone Receptor Positive ◽  
Er Positive ◽  
Adjuvant Breast Cancer ◽  
Great Appreciation ◽  
Positive Breast Cancer

Overview: There is great appreciation for the heterogeneity of breast cancers, particularly of hormone-receptor positive breast cancers. A goal of modern oncology managing such heterogeneity is to determine how to individualize therapy based on the specific pathological and biological features of a given tumor. Two distinctive clinical literatures exist to guide treatment of hormone-receptor-positive breast cancer. The Oxford Overview, a seminal meta-analysis effort, has recently been updated, and suggests that nearly all patients with ER-positive tumors benefit from adjuvant endocrine therapy. In addition, the overview finds that nearly all subsets of patients with ER-positive tumors also benefit from modern adjuvant chemotherapy regimens. Meanwhile, retrospective subset analyses of specific trials or populations suggests that the benefits of chemotherapy are not so uniform, and in particular that molecular diagnostics assays can identify patients who do not warrant chemotherapy. This article will highlight recent data and controversies in personalizing adjuvant breast cancer therapy.

Tidal chemotherapy in premenopausal patients with hormone receptor positive breast cancer

2017 ◽  
Vol 102 ◽  
pp. 4-7
Author(s):  
Qing-qing Luo ◽  
Jian-bo Huang ◽  
Yu-tuan Wu ◽  
Xin Li ◽  
Chun-xia Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Hormone Receptor Positive ◽  
Premenopausal Patients ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document